Dermatology News Roundup: Bimzelx Expansion, Zoryve sNDA, and HS Insights
核心洞察
Bimzelx gains FDA approval for active psoriatic arthritis (搜索), non-radiographic axial spondyloarthritis, and ankylosing spondylitis (搜索), marking it as the first IL-17A/F inhibitor for four immune-mediated diseases.
Arcutis' Zoryve foam sNDA accepted by the FDA for scalp and body psoriasis (搜索), supported by phase 2b and 3 data showing symptom improvement and safety, with a target action date set for May 2025.
Semaglutide shows potential in reducing flare-ups and improving quality of life for hidradenitis suppurativa (搜索) patients, suggesting weight loss medications could complement existing treatments.
Bimekizumab (Bimzelx) has received FDA approval for three new indications: active psoriatic arthritis (搜索), active non-radiographic axial spondyloarthritis with inflammation, and active ankylosing spondylitis (搜索). This approval marks bimekizumab as the first IL-17A and IL-17F (搜索) inhibitor approved for four chronic immune-mediated inflammatory diseases in the US. The approval was based on Phase 3 trials demonstrating significant improvements in joint and skin symptoms at 16 weeks, sustained through 52 weeks.
Arcutis Biotherapeutics' supplemental New Drug Application (sNDA) for roflumilast (Zoryve) foam 0.3%, targeting scalp and body psoriasis (搜索) in patients aged 12 and older, has been accepted by the FDA, with a Prescription Drug User Fee Act target date of May 22, 2025. The sNDA is supported by positive data from Phase 2b and Phase 3 trials, showing significant improvements in scalp and body psoriasis symptoms compared to placebo, along with favorable safety results. Patrick Burnett, MD, PhD, FAAD, chief medical officer of Arcutis, stated, "It is critical that our clinical data represent the diversity in the world around us, and these results further reinforce our commitment to providing meaningful innovation for immune-mediated skin diseases."
Semaglutide and Hidradenitis Suppurativa
Early findings suggest that semaglutide, known for its weight loss benefits, may also help reduce flare-ups in patients with hidradenitis suppurativa (搜索) (HS). Even at lower doses, semaglutide appears to improve patients' quality of life by managing both weight and HS symptoms. Researchers are advocating for larger trials to confirm these initial results and encouraging dermatologists to consider weight loss medications as adjuncts to existing HS treatments.
Additional Highlights
The Epidermolysis Bullosa (搜索) Medical Research Foundation (EBMRF) raised over $1 million for epidermolysis bullosa (EB) research at its 7th annual Rock4EB! concert. Additionally, researchers have successfully transformed giant panda skin cells into pluripotent stem cells, potentially advancing conservation efforts for the endangered species.